[1] Passweg J R, Baldomero H, Bader P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for blood and marrow transplant activity survey report[J]. Bone Marrow Transplant, 2018, 53(9): 1139-1148. [2] Ballen K K, Gluckman E, Broxmeyer H E. Umbilical cord blood transplantation: the first 25 years and beyond[J]. Blood, 2013, 122(4): 491-498. [3] Terakura S, Atsuta Y, Tsukada N, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia[J]. Biol Blood Marrow Transplant, 2016, 22(2): 330-338. [4] Martin P J, Lee S J, Przepiorka D, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. the 2014 clinical trial design working group report[J]. Biol Blood Marrow Transplant, 2015, 21(8): 1343-1359. [5] 费倩, 黄晓军, 刘扬, 等. 单倍型造血干细胞移植治疗伴骨髓增生异常综合征相关特征急性髓系白血病临床分析[J]. 中华血液学杂志, 2018, 39(7): 546-551. [6] 郑凤美, 张曦, 李春富, 等. 单倍体和同胞全相合移植治疗高危小儿AML的疗效比较: 一项多中心临床研究[J]. 癌症, 2020, 39(10): 455-466. [7] Wang Y, Liu Q F, Xu L P, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study[J]. Blood, 2015, 125(25): 3956-3962. [8] Wagner J E, Gluckman E. Umbilical cord blood transplantation: the first 20 years[J]. Semin Hematol, 2010, 47(1): 3-12. [9] Fatobene G, Storer B E, Salit R B, et al. Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation[J]. Haematologica, 2019, 104(4): 835-843. [10] Sarvaria A, Basar R, Mehta R S, et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation[J]. Blood, 2016, 128(10): 1346-1361. [11] Hiwarkar P, Qasim W, Ricciardelli I, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells[J]. Blood, 2015, 126(26): 2882-2891. [12] Eapen M, Klein J P, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy[J]. Blood, 2014, 123(1): 133-140. [13] Nakasone H, Tabuchi K, Uchida N, et al. Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells?[J]. Br J Haematol, 2019, 185(1): 166-169. [14] Dehn J, Spellman S, Hurley C K, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR[J]. Blood, 2019, 134(12): 924-934. [15] Hough R, Danby R, Russell N, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols[J]. Br J Haematol, 2016, 172(3): 360-370. [16] 朱江, 汤宝林, 宋闿迪, 等. 非血缘脐血干细胞移植与同胞造血干细胞移植治疗MDS-EB和AML-MRC的对比观察[J]. 中华血液学杂志, 2019, 40(4): 294-300. |